Worth Watching: Cipher Pharmaceuticals Inc’s Stock Is Buy After Today’s Big Increase

Worth Watching: Cipher Pharmaceuticals Inc's Stock Is Buy After Today's Big Increase

The stock of Cipher Pharmaceuticals Inc (NASDAQ:CPHR) is a huge mover today! About 73,064 shares traded hands or 1072.97% up from the average. Cipher Pharmaceuticals Inc (NASDAQ:CPHR) has declined 24.62% since March 29, 2016 and is downtrending. It has underperformed by 28.10% the S&P500.
The move comes after 7 months positive chart setup for the $91.37M company. It was reported on Oct, 31 by Barchart.com. We have $7.22 PT which if reached, will make NASDAQ:CPHR worth $83.15 million more.

Analysts await Cipher Pharmaceuticals Inc (NASDAQ:CPHR) to report earnings on November, 2. They expect $-0.05 EPS, down 25.00% or $0.01 from last year’s $-0.04 per share. After $-0.06 actual EPS reported by Cipher Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts -16.67% EPS growth.

Cipher Pharmaceuticals Inc (NASDAQ:CPHR) Ratings Coverage

Out of 2 analysts covering Cipher Pharma (NASDAQ:CPHR), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Cipher Pharma has been the topic of 2 analyst reports since November 30, 2015 according to StockzIntelligence Inc. The stock has “Outperform” rating given by CBIC on Monday, November 30. The rating was initiated by IBC on Monday, November 30 with “Sector Outperform”.

According to Zacks Investment Research, “Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company. It develops improved formulations of existing drugs. The Company’s core capabilities include clinical and regulatory affairs, product licensing, supply chain management, and marketing and sales. It has three commercial products and a fourth in development. The Company’s products include a fenofibrate formulation marketed in the United States as Lipofen (R); an extended-release tramadol, which is marketed in the United States as ConZip (R) and in Canada as Durela (R); and a novel formulation of the acne treatment isotretinoin, which is marketed in the United States as Absorica (TM) and in Canada as Epuris (R). Cipher Pharmaceuticals Inc. is based in Mississauga, Canada.”

More notable recent Cipher Pharmaceuticals Inc (NASDAQ:CPHR) news were published by: Prnewswire.com which released: “Cipher Pharmaceuticals Inc. Announces Changes to its Board of Directors” on August 09, 2016, also Prnewswire.com with their article: “Notice of Cipher Pharmaceuticals Inc. Q3 2016 Conference Call” published on October 27, 2016, Prnewswire.com published: “Cipher Pharmaceuticals Responds to Request for Comment from IIROC” on October 31, 2016. More interesting news about Cipher Pharmaceuticals Inc (NASDAQ:CPHR) were released by: Prnewswire.com and their article: “Cipher Pharmaceuticals acquires assets of Melanovus Oncology Inc.” published on January 09, 2015 as well as Prnewswire.com‘s news article titled: “Cipher Pharmaceuticals Inc. announces Sitavigâ„¢ accepted for review by Health …” with publication date: February 16, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment